新型抗凝剂甲磺酸萘莫司他在血液净化中的应用：现状与前景

苟 淑娟1, 张 斌*2
1、青海大学临床医学院
2、青海省人民医院

摘要


随着血液净化技术的不断进步，抗凝剂的选择对治疗效果和患者的安全性变得尤为重要。血液净化中体外抗凝是一项巨大挑战，甲磺酸萘莫司他作为一种新型抗凝剂，因其独特的作用机制和抗凝的安全性，逐渐受到临床研究者的关注。近年来的研究显示，甲磺酸萘莫司他在血液净化中的应用不仅能够有效抗凝、提高滤器使用寿命，而且还能降低出血风险。然而，目前关于其药理特性和临床效果的研究仍显不足。与传统抗凝剂的比较研究也亟待加强。本文综合现有文献，探讨甲磺酸萘莫司他在血液净化中的应用现状及未来可能的研究方向，旨在为临床实践提供参考，深入了解其潜在价值。

关键词


甲磺酸萘莫司他；抗凝剂；血液净化；药理特性；临床应用

全文:

PDF


参考


[1]Spasov AA, Fedorova OV, Rasputin NA, et al. Novel Substituted Azoloazines with Anticoagulant Activity. Int J Mol Sci. 2023;24(21). Published 2023 Oct 25. doi:10.3390/ijms242115581

[2]Yaniv D, Zavdy O, Sapir E, Levi L, Soudry E. The Impact of Traditional Anticoagulants, Novel Anticoagulants, and Antiplatelets on Epistaxis. Laryngoscope. 2021;131(9):1946-1951. doi:10.1002/lary.29417

[3]Yin Q, Zhang X, Liao S, Huang X, Wan CC, Wang Y. Potential anticoagulant of traditional chinese medicine and novel targets for anticoagulant drugs. Phytomedicine. 116:154880. doi:10.1016/j.phymed.2023.154880

[4]Koolian M, Wiseman D, Mantzanis H, Kampouris N, Kerzner RS, Kahn SR. Anticoagulation stewardship: Descriptive analysis of a novel approach to appropriate anticoagulant prescription. Res Pract Thromb Haemost. 2022;6(6):e12758. Published 2022 Aug. doi:10.1002/rth2.12758

[5]KOSHIYAMA Y,OZEKIM M,MOTOYOSHIA,et al.Pharmacological studies of FUT-175,nafamstat mesilate .IV: effects on coagulation,platelets and fibrinolysis [J].Nihon Yakurigaku Zasshi,1984,84(5):417-428.

[6]MATSUOKA S, FUTAGAMI M, OHNOH, et al. Inhibitory effects of ONO-3307on various proteasesand tissue thromboplastin initro and on experimental thrombosisinio[J]. JpnJ Pharmacol, 1989, 51 (4): 455-463. DOI: 10.1016/s0021-5198(19) 40071-1.

[7]MIYATA M, SHIRAKAWA T, ACHARYA B, et al. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients [J]. ASAIOJ, 2006, 52(3): 272-275. DOI: 10.1097/01. mat. 0000209224. 94089. bc.

[8]IWAKIM, INO Y, MOTOYOSHI A, et al. Pharmacological studies of FUT-175,n

[9]afamostat mesilate V: effects on the pancreatic enzymes and experimental acute pancreatitisin rats [J]. JpnJ Pharmacol, 1986, 41 (2): 155-162. DOI: 10.1254/jjp.41.155.

[10]Odagaki Y, Mikami M, Kinoshita M, et al. Agonistic properties of a series of psychotropic drugs at 5-HT1A receptors in rat and human brain membranes determined by [35S]GTPγS binding assay. Pharmacol Rep. 2023;75(2):266-275. doi:10.1007/s43440-023-00448-6

[11]Isayama N, Matsumura G, Uchimura Y, Maeda E, Sasaki K. Utility and safety of nafamostat mesilate for anticoagulation in dogs. Vet Med Sci. 2023;9(1):68-75. doi:10.1002/vms3.1002

[12]Moon K, Hong KW, Bae IG. Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial. Trials. 2021;22(1):832. Published 2021 Nov 23. doi:10.1186/s13063-021-05760-1

[13]Kitaura A, Iwamoto T, Hamasaki S, Tsukimoto S, Nakajima Y. Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance. Cureus. 2023;15(8):e44003. Published 2023 Aug. doi:10.7759/cureus.44003

[14]Yang H, Feng J, Ma Y, Ma X, Li X, . Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial. Trials. 2025;26(1):262. Published 2025 Jul 29. doi:10.1186/s13063-025-08979-4

[15]Quinn TM, Gaughan EE, Bruce A, et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine. 76:103856. doi:10.1016/j.ebiom.2022.103856

[16]Takada S, Suzuki S, Tamura T. Low molecular weight heparin-induced thrombocytopenia management during hemodialysis and cardiac surgery: a case report and literature review. JA Clin Rep. 2025;11(1):18. Published 2025 Mar 28. doi:10.1186/s40981-025-00781-0

[17]Michael N, Grigoryan MM, Kilday K, et al. Effects of Dabigatran in Mouse Models of Aging and Cerebral Amyloid Angiopathy. Front Neurol. 10:966. Published 2019 None. doi:10.3389/fneur.2019.00966

[18]Xiao X, Zhu W, Dai Q. Direct Oral Anticoagulants Versus Traditional Anticoagulation in Cirrhotic Patients with Portal Vein Thrombosis: Updated Systematic Review. Clin Appl Thromb Hemost. 30:10760296241303758. doi:10.1177/10760296241303758

[19]Sahu AK, Katheria A. Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? - New insights from RIVER trial. Indian Heart J. 2021 Jul-Aug;73(4):516-517. doi:10.1016/j.ihj.2021.06.019

[20]Wu X, Liang L, Liu J. Effect of Direct Oral Anticoagulants Versus Traditional Anticoagulation in Budd-Chiari Syndrome. Clin Appl Thromb Hemost. 31:1076029

[21]6251384904. doi:10.1177/10760296251384904

[22]Zhan QY, Xie LX, Wang C. [Promoting critical care system and capacity building in pulmonary and critical care medicine subspecialties]. Zhonghua Yi Xue Za Zhi. 2023;103(40):3149-3151. doi:10.3760/cma.j.cn112137-20230602-00919

[23]Gao H, Chen M, Huang Y, Liu H, Lin Y, Chen M. Efficacy and safety of antithrombotic therapy for preventing and treating pediatric thromboembolic disease: a systematic review. Sci Rep. 2024;14(1):13378. Published 2024 Jun 11. doi:10.1038/s41598-024-64334-8

[24]Munshi R, Pilliwar C, Maurya MR. Public disclosure of clinical trial results at Clinical Trial Registry of India- Need for transparency in research! Perspect Clin Res. 2023 Apr-Jun;14(2):81-85. doi:10.4103/picr.picr_39_22

[25]Strayer TE, Hollingsworth EK, Shah AS, Vasilevskis EE, Simmons SF, Mixon AS. Why do older adults decline participation in research? Results from two deprescribing clinical trials. Trials. 2023;24(1):456. Published 2023 Jul 18. doi:10.1186/s13063-023-07506-7

[26]Strayer T, Hollingsworth E, Shah A, Vasilevskis E, Simmons S, Mixon A. Why do Older Adults Decline Participation in Research? Results from Two Deprescribing Clinical Trials. Res Sq. . Published 2023 Apr 28. doi:10.21203/rs.3.rs-2814339/v1

[27]He Z, Yang L, Li X, Du J. Discrepancies in reported results between trial registries and journal articles for AI clinical research. EClinicalMedicine. 80:103066. Published 2025 Feb. doi:10.1016/j.eclinm.2024.103066

[28]Khwaja A. KDIGO clinical practice guideline for acute kidney injury. Nephron Clin Pract, 2012, 120(4): c179-c184.

[29]陈香美.血液净化标准操作规程（2021版）.人民卫生出版社，2021：150-154.

[30]北村伸哉，张凌.甲磺酸萘莫司他在连续性肾脏替代治疗中的抗凝应用U1.华西医学，2018，33（7）：801-805.

[31]国家慢性肾病临床医学研究中心，中国医师协会肾脏内科医师分会，中国急性肾损伤临床实践指南专家组.中国急性肾损伤临床实践指南 中华医学杂志，2023，103（42）：3332-3366.

[32]Bolli R, Tang XL. Clinical trials of cell therapy for heart failure: recent results warrant continued research. Curr Opin Cardiol. 2022;37(3):193-200.

[33]Xie YQ, Hu JC, Shen B, et al. [Anticoagulation effects of nafamostat mesylate in sustained low-efficiency dialysis and its relevant factors]. Zhonghua Yi Xue Za Zhi. 2025;105(2):163-170. doi:10.3760/cma.j.cn112137-20240908-02067

[34]Xiaobo M, Qiuxin C, Zhenhua Y, Xiaoting P, Xiaonong C. Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy. Front Pharmacol. 16:1592562. Published 2025 None. doi:10.3389/fphar.2025.1592562

[35]Yang T, Yu W, Guo D, et al. Difference in the inhibitory mechanism against TMPRSS2 between camostat and nafamostat: implications for drug design. Phys Chem Chem Phys. 2025;27(35):18539-18554. Published 2025 Sep 10. doi:10.1039/d5cp02191j

[36]David S, Rimmelé T, Joannidis M, et al. Knowledge gaps in extracorporeal blood purification: what would be required for its successful application in septic shock? Intensive Care Med Exp. 2025;13(1):118. Published 2025 Nov 21. doi:10.1186/s40635-025-00819-8

[37]Jia J, Meng D, Zhang X, et al. Clinical application of blood purification in polymyositis/dermatomyositis. Ther Apher Dial. 2024;28(1):112-118. doi:10.1111/1744-9987.14072

[38]Chinese expert consensus on the establishment and application of vascular access of critical care blood purification (2023)]. Zhonghua Yi Xue Za Zhi. 2023;103(17):1280-1295. doi:10.3760/cma.j.cn112137-20220915-01949

[39]Tsujimoto H, Tsujimoto y, Nakata y,et al. ph arma co logical in ter vent ions for preventing clotting of extra corporeal circuits during continuous renal replacement therapy UI. cochrane Database syst Rev,2020,12(12): D12467.

[40]zar bock A, kull marM, kind gen-Mille sD, et al. Ef ect ofRe gional citrate Anti coagulation vs systemic Hep arin A ntico agu lat ion During continuous kidney Replacement Therapy on Dialysis Filter Life span and Mortality Among critically Ill patients with Acute kidney Injury: A Randomized clinical Trial u1JAMA,2020,324(16):1629-1639.

[41]Le grand M,Tolw ani A. Anti coagulation strategies in conti nu ous renal replacement therapy u1. seminars in Dialysis,2021,34(6)

[42][17oh HS, kim T, GUD, et al. ph arma co kinetics of Naf amos tat, a potent seri ne protease Inhibitor, by a Novel LC-MS/MS Anal ysi sJ]. Molecules,2022,27(6):1881.


Refbacks

  • 当前没有refback。